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Background: A select number of relatively rare metastatic malignancies comprising trophoblast tumours, the rare
childhood cancers, germ cells tumours, leukemias and lymphomas have been routinely curable with chemotherapy for
more than 30 years. However for the more common metastatic malignancies chemotherapy treatment frequently
brings clinical benefits but cure is not expected. Clinically this clear divide in outcome between the tumour types can
appear at odds with the classical theories of chemotherapy sensitivity and resistance that include rates of proliferation,
genetic development of drug resistance and drug efflux pumps. We have looked at the clinical characteristics of the
chemotherapy curable malignancies to see if they have any common factors that could explain this extreme differential
sensitivity to chemotherapy.
Discussion: It has previously been noted how the onset of malignancy can leave malignant cells fixed with some
key cellular functions remaining frozen at the point in development at which malignant transformation occurred.
In the chemotherapy curable malignancies the onset of malignancy is in each case closely linked to one of the
unique genetic events of; nuclear fusion for molar pregnancies, choriocarcinoma and placental site trophoblast
tumours, gastrulation for the childhood cancers, meiosis for testicular cancer and ovarian germ cell tumours and
VDJ rearrangement and somatic hypermutation for acute leukemia and lymphoma. These processes are all linked
to natural periods of supra-physiological apoptotic potential and it appears that the malignant cells arising from
them usually retain this heightened sensitivity to DNA damage. To investigate this hypothesis we have examined
the natural history of the healthy cells during these processes and the chemotherapy sensitivity of malignancies
arising before, during and after the events.
Summary: To add to the debate on chemotherapy resistance and sensitivity, we would argue that malignancies
can be functionally divided into 2 groups. Firstly those that arise in cells with naturally heightened apoptotic
potential as a result of their proximity to the unique genetic events, where the malignancies are generally
chemotherapy curable and then the more common malignancies that arise in cells of standard apoptotic
potential that are not curable with classical cytotoxic drugs.
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In the modern era of cancer therapies with designated
targets and molecularly designed pathway inhibitors, the
concept that crude DNA damaging cytotoxic chemother-
apy agents could lead to successful treatment and the cure
of some malignancies with minimal long term toxicity [1]
would appear both old fashioned and unlikely. However
the use of cytotoxic chemotherapy drugs to treat malig-
nancies has been an integral part of cancer care since
the 1950s [2] and in the treatment of a limited number
of malignancies it has been spectacularly successful [3].
In the first 25 years of cytotoxic chemotherapy clinical
drug development, there were dramatic advances in care
that led to patients with a select number of relatively
rare malignancies becoming routinely curable. By the
end of the 1970s, the outlook for patients with gesta-
tional trophoblast tumours, testicular and ovarian germ
cell tumours, acute leukaemia, Hodgkin’s lymphoma,
high grade non-Hodgkin’s lymphoma and some of the
childhood malignancies had been transformed with cure
by then a realistic routine outcome [4].
With advances in drug delivery and supportive care,
the majority of patients currently diagnosed with these
rare malignancies can now expect curative treatment
with the use of chemotherapy drugs that were all almost
entirely developed before the 1980s. In contrast, despite
the subsequent introduction of an additional 30 cyto-
toxic chemotherapy drugs and complex methods of
delivery including high dose chemotherapy with stem
cell rescue, the outlook for patients with the other more
common types of metastatic cancers including breast,
ovary, lung, prostate, colon, pancreas and melanoma re-
mains one of disease control, improving life expectancy
but without any significant chance of cure [4]. This
divergent response to the same drugs used in the
chemotherapy curable malignancies and those where the
same cytotoxic chemotherapy drugs bring important
benefits but not cure, remains one of the major chal-
lenges in clinical practice and cancer research [5-7].
It is apparent that the response to DNA damage from
radiation therapy or chemotherapy can lead cells to
proceed to either DNA repair or the induction of apop-
tosis [8]. The pathway taken in this divergent response is
linked to the treatment dose and hence amount of DNA
damage achieved [9] however it is clear that differing
tumour types have dramatically differing thresholds for
the effective induction of apoptosis as opposed to pro-
ceeding with DNA repair.
Over the past 30 years there has been with much
research into this issue, looking at the postulated mecha-
nisms of chemotherapy resistance and how to potentially
overcome these barriers [10-12]. Historically the sensi-
tivity and resistance of cancer cells to chemotherapy has
been linked to the rate of cell division [13], the structureof the tumour cell DNA, the number of tumour cells
and the subsequent risk of development of resistant
clones [14,15], the presence of drug efflux pumps [16],
reduction in DNA repair mechanisms [17] and for the
curable cancers their relationship to primitive stem cells
and a wide range of additional factors [12,18]. More
recent data has raised issues regarding these concepts
and the relationship between responses or resistance
to chemotherapy and these previously established
principles seems less secure [19-21]. From the clinical
perspective these concepts of the determinants of
chemotherapy curability can appear challenging, with
the high levels of chemotherapy curability seen reli-
ably in a selective number of tumours and the lack of
a clear clinical relationship between the rate of growth
of the chemotherapy curable tumours, which is fre-
quently relatively slow and the often extreme bulk of
the curable malignancies that appear to only rarely
give rise to chemotherapy resistant clones.
In contrast, based on the key clinical characteristics of
the chemotherapy curable malignancies, we have previ-
ously outlined a differing hypothesis behind the dramat-
ically different outcomes to treatment between the rare
chemotherapy curable malignancies and the other more
common malignancies. We observe that each of the
chemotherapy curable malignancies arises in a cell type
that normally has a complex developmental path of
differentiation into its mature progeny. During their devel-
opment these cell types each undergo a specialised unique
genetic process; nuclear fusion, gastrulation, meiosis,
immunoglobulin/T cell receptor gene VDJ rearrangement,
somatic hypermutation and class switching. These pro-
cesses are each naturally intrinsically associated with
heightened pro-apoptotic pathway activity [22,23]. The
onset of these processes allows the normal healthy cell
and its transformed malignant variant to have an exag-
gerated apoptotic response to both intrinsic DNA dam-
age and also to chemotherapy induced therapeutic DNA
damage. This response is both dramatically higher than
that for normal cancer cells, but is also higher than that
of the stem cells from which the malignant cell is
derived.
It has previously been noted how the onset of malig-
nancy during B lymphocyte development appears to
leave the malignant cell ‘frozen’ at that developmental
state [24,25]. Building on this hypothesis and the possi-
bility that chemotherapy curable cancers are intrinsically
different from normal tumours [26] this theory has been
further developed for the wider group of chemotherapy
curable malignancies. We have noted that the ‘frozen’
state also includes the up regulated pro-apoptotic pro-
cesses and sensitivity that were naturally associated with
the processes of DNA manipulation in action at the time
of the development of the malignant phenotype [27].
Savage BMC Cancer  (2015) 15:11 Page 3 of 25In the clinical setting the large majority of malignan-
cies arising at these key genetic points in these develop-
ing cells retain this dramatic sensitivity to DNA damage
via the retention of their specialised pro-apoptotic path-
ways. This sensitivity can then be exploited with chemo-
therapy treatment despite the potentially long interval
from the original malignant change through to diagnosis
and treatment often many years later.
In this update we will review, from the clinical per-
spective with a focus on the phenomenon rather than
the detailed mechanisms involved, the clinical and basic
scientific data as to how this hypothesis may be applic-
able across the range of chemotherapy curable malig-
nancies and consider how future therapeutic endeavours
could exploit these processes.Table 1 A summary of the unique genetic events associated w
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Gestational choriocarcinoma Nuclear Fusion 95%
PSTT Nuclear Fusion 49%
Germ cell tumours
Testicular cancer Meiosis 90%






B ALL VDJ rearrangement Child 85%
Adult 53%
T ALL VDJ rearrangement Child 75%















ALK + ve anaplastic large cell
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Review of metastatic malignancy chemotherapy curability
In 2015 it is perhaps challenging to understand quite
the impact produced by the early success of cytotoxic
chemotherapy treatment. The revolution in care that
took place from 1955–1980 is perhaps the most dra-
matic that will be seen in cancer treatment develop-
ment. In this period a number of malignancies that
predominantly affected younger patients and were pre-
viously nearly uniformly fatal moved to becoming rou-
tinely curable, both in the major academic centres and
also in routine clinical care [3,28].
In Table 1 the chemotherapy curable metastatic malig-
nancies are listed along with representative treatment











Bleomycin, Etoposide, Cisplatin [32]
Bleomycin, Etoposide, Cisplatin [33]



























Savage BMC Cancer  (2015) 15:11 Page 4 of 25current care. Of note, all but one of the drugs currently
routinely used in the standard regimens employed in
these chemotherapy curable malignancies were intro-
duced to routine practice at least 30 years ago, with
etoposide the last one added in 1982. These drugs were
developed at a time when there was significantly less
understanding about the metabolism, targets or pathway
defects in cancer cells and the overall research budget
only a fraction of the current one.
There have been nearly 30 additional classical cyto-
toxic drugs licensed since the arrival of etoposide but
none currently form part of the routine first line regi-
mens for the chemotherapy curable malignancies [45].
Of the total of 78 new cancer treatment drugs of all
therapeutic classes introduced during this time period,
only one Rituximab, currently forms part of the routine
treatment of a chemotherapy curable metastatic malig-
nancy and then as an addition to therapy rather than a
substitution of an earlier drug [42].
This data on the timeline of the key chemotherapy
drugs used in the chemotherapy curable malignancies
raises a key question that can be looked at in two differ-
ing ways; Why have there been no better drugs devel-
oped for treating these chemo-curable malignancies and
extending curability to other malignancies developed
since 1980, or alternatively what is different or special
about these malignancies that made them so dramatic-
ally responsive to these early empirical chemotherapy
drugs that the past 30 years of research and drug devel-
opment has not been able to improve upon or extend to
other tumor types?
Historical explanations for this extreme sensitivity to
chemotherapy and the divergence in curability have been
based on concepts including a higher growth rate for the
curable cancers, the mutation of cells into drug resistant
clones, the development of drug efflux pumps and the
relationship of curable cancers to stem cells. However
routine clinical observations indicate that the malignan-
cies that are routinely chemotherapy curable occur in
differing anatomical locations, present at differing ages
and having differing clinical presentations and varying
pace of growth. These can range from the very rapidly
growing acute leukemias and gestational choriocarcin-
oma to the frequently slow growing, post molar preg-
nancy gestational trophoblast tumors, Hodgkin’s disease
and testicular seminoma. Additionally the tumour types
that are chemotherapy curable are more sensitive to
chemotherapy drugs than their native stem cells and can
in the case of B cell lymphoma have intermediary devel-
opment stages and malignancies that are less sensitive to
chemotherapy than in the further malignancies occur-
ring later in B cell development.
These clinical observations indicate that the malignan-
cies that are chemotherapy curable each arise in cellsthat are associated with physiologically unique genetic
events and that the highly up regulated pro-apoptotic
processes that naturally accompany these events are
maintained in the associated malignancies.
The unique genetic processes occurring in the chemo-
therapy curable malignancies are nuclear fusion for
molar pregnancies, gestational choriocarcinoma and
placental site tumors, gastrulation for the rare child-
hood malignancies, meiosis for the testicular and ovarian
germ cell tumours, VDJ rearrangements for B cell and T
cell ALL, acute myeloid leukemia and anaplastic large cell
lymphoma and immunoglobulin gene somatic hypermu-
tation for Hodgkin’s lymphoma and diffuse large B cell
lymphoma (DLBCL).
Our hypothesis is that these chemo-curable malig-
nancies are a unique group of malignancies that whilst
arising at different time points and from differing cells
lines, all share the presence of hugely up regulated
pro-apoptotic pressures that were present in these cells
as part of their natural activity during a normal but
unique genetic activity occurring in these cells at the
time of the development of the malignant phenotype.
As a result of the malignant change the cells appear
to be held developmentally frozen and poised to poten-
tially naturally undergo apoptosis in response to either
natural or therapeutic DNA damage. Within this
scenario the chemotherapy drugs, particularly when
used in combination exploit this situation, producing
massive levels of apoptosis that the newer drugs are
unable to improve significantly on. The links between
these genetic events, the clinical presentations and
treatment outcomes for the differing groups of malig-
nancies are discussed below.Gestational Trophoblast Tumours [GTT]
Post molar pregnancy-GTT
The process of nuclear fusion, the joining together of
the nucleus of the oocyte and that of the sperm, is com-
plex and frequently ends in failure rather than the
successful creation of a viable embryo. The complex
process also includes the second meiotic division of the
oocyte, a process that happens a number of decades after
the first meiotic division which occurred in utero.
Oocytes that are not fertilised appear to die via apop-
tosis [46] with the progression to this natural process
being inhibited by successful fertilisation [47]. Similarly
in spermatogenesis, apoptosis is a routine part of the
process with estimates of losses of 70% reported [47].
More recent data has indicated that normal healthy
sperm have active apoptotic characteristics and are
destined to naturally die an apoptotic death, and hence
avoid a potential inflammatory and immunogenic death,
unless rescued by fertilising the egg [48].
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apoptosis are still exhibited and many zygotes, predominately
those with genetic abnormalities, die an apoptotic death
shortly after fertilisation [49,50]. Additionally apoptosis
is actively involved in balancing the numbers of cell
within the blastocyst and inner cell mass [51] and the
second polar body, the product of the second meiotic
division of the oocyte that is produced at the time of
fertilisation, is also lost by undergoing apoptosis [52,53].
The pro-apoptotic pressures appear to remain active
initially after nuclear fusion and the newly fertilised hu-
man egg remains extremely sensitive to DNA damaging
agents. In response to very low doses of chemotherapy
the cells of the new fertilised egg and developing embryo
readily undergo apoptosis. In ectopic pregnancies a sin-
gle 50–100 mg dose of methotrexate is usually adequate
to kill the cells [54]. Similarly when used to induce a
medical termination, similar low doses of methotrexate
are also able to terminate pregnancies through to 8 weeks
gestation with near 90% effectiveness [55]. In contrast by
the end of the first trimester the cells are generally resist-
ant to chemotherapy and maternal malignancies can be
treated with full dose combination chemotherapy without
any detectable detriment to the foetus or placenta [56]. In
post molar pregnancy gestational trophoblast tumours, it
appears that this extraordinary sensitivity to DNA damage
that is associated with nuclear fusion, can remain in place
virtually indefinitely and so gives this diagnosis its great
sensitivity to chemotherapy [29].
Molar pregnancies have characteristic abnormal gen-
etic structures with partial molar pregnancies having
two sets of paternal chromosomes and one set of mater-
nal chromosome [57] and complete molar pregnancies
having two sets of paternal but no maternal chromo-
somes [58]. As a result, the cells of the molar pregnancy
are genetically and structurally abnormal from the point
of conception and we would hypothesise that in molar
pregnancies the natural apoptotic processes existing at
the time of nuclear fusion do not become down regu-
lated, as they do in a normal pregnancy, despite the mul-
tiple division of the cells and growth of the molar tissue.
Low dose methotrexate was first successfully used in
the treatment of post molar pregnancy gestational
trophoblast tumours in 1956 [2] and protocols based on
low dose methotrexate remain the standard of care at
most treatment centres [29,59]. A routine example of
the rapid response treatment and curative outcome for a
patient with post molar pregnancy gestational tropho-
blast tumours is shown in Figure 1. Overall 100% of
patients with post molar pregnancy gestational tropho-
blast tumours can be cured with chemotherapy, with the
majority only requiring therapy with doses of methotrex-
ate that would be sub-therapeutic and have little activity
in other malignancies [29].Gestational Choriocarcinoma and Placental Site
Trophoblast Tumour [PSTT]
Gestational choriocarcinoma is a rare malignancy and
has an incidence in the range of approximately 10–20
cases per million conceptions [60]. The typical pre-
sentation of gestational choriocarcinoma is of a rapidly
growing, hCG producing malignancy occurring in
women after a normal pregnancy with frequently wide-
spread metastatic spread with the CNS, lung and liver
common disease sites. Despite the disseminated pattern
of metastatic spread and the frequent rapid growth of
the tumour cells the large majority of cases of cho-
riocarcinoma are routinely curable with combination
chemotherapy [30].
Clinical data from the care of a patient with gestational
choriocarcinoma are demonstrated in Figure 2, showing
the prompt hCG tumour marker response and complete
radiological response of the multiple lung metastases
to chemotherapy treatment. The patient remains well
nearly 10 years later, has had a further healthy child
and has a negligible risk of relapse.
In gestational choriocarcinoma the malignant cells arise
from previously genetically normal cells of a normal con-
ception that have successfully moved through fertilisation
and nuclear fusion. In embryogenesis the differentiated
trophoblast cells start to develop at approximately 3 days
post fertilisation, as the cells of the morula differentiate
into the outer trophoblast cells and the inner cell mass.
Whilst the cells of the inner cell mass go onto form the
embryo, it is the cytotrophoblastic cells in the outer com-
ponent that can become transformed and appear to be the
cell of origin of gestational choriocarcinoma [61].
Placental site trophoblast tumour [PSTT] is a rarer
diagnosis with an incidence of approximately 2–5 cases
per million pregnancies. In contrast to choriocarcinoma,
PSTT develops from a transformed cell that arises later
in the development of the placenta. The cells of origin of
PSTT are the implantation site intermediate trophoblast
cells [62,63] which develop later in the pregnancy be-
coming apparent at approximately 13–16 days post con-
ception [R Kurman pers comm].
Compared to post molar pregnancy GTT, the cellular
points of origin of both gestational choriocarcinoma and
PSTT are significantly different occurring from a normally
fertilised egg and from further along the development
route after the initial fertilisation and nuclear fusion. This
increased temporal distance from the unique genetic event
of nuclear fusion parallels the clinical observation of the
rising intensity of chemotherapy needed to cure these
tumours. Overall gestational choriocarcinoma is usually
curable with chemotherapy but single agent low dose
methotrexate is rarely effective [64] and more intensive
combination regimens are needed to give curative treat-
ment for most patients [30]. In PSTT the malignant
Figure 1 Post molar pregnancy gestational trophoblast tumour. Pre and post treatment MRI scans of the pelvis showing a large uterine
mass prior to treatment and a normal scan at completion. The treatment graph shows the fall and normalisation of the hCG level with low dose
methotrexate chemotherapy treatment. The patient has completed treatment, gone on to have a healthy baby and has been cured of this malignancy.
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that is further removed from the nuclear fusion event.
In this diagnosis, combination chemotherapy can be
curative in many patients with metastatic disease but
the overall cure rates of 49% are significantly lower than
in post molar pregnancy gestational trophoblast tu-
mours or gestational choriocarcinoma [31].
In choriocarcinoma and PSTT, in addition to the im-
portance of the genetic distance the tumour arises from
the nuclear fusion event, the interval from the ante-
cedent pregnancy to the time of diagnosis and treatment
appears to have a significant impact on chemotherapy
curability. In choriocarcinoma, patients with a longer
interval from the antecedent pregnancy to presentation
have an enhanced risk of refractory disease and treat-
ment failure [65] and whilst cases of PSTT presenting
with an interval of less than 48 months have a good
prognosis those with a longer interval are rarely cured
[31]. It is unclear if these changes in curability mark the
loss of the pro-apoptotic pathways occurring with the
increasing interval from the antecedent pregnancy or if
the cases of choriocarcinoma or PSTT arising later inthe development of the trophoblast and hence more
distant from nuclear fusion have both a more slow grow-
ing natural history, later presentation and also a poorer
response to chemotherapy.
Childhood malignancies
The successful treatment of the rare childhood malig-
nancies including Ewing’s sarcoma, Wilms tumours,
osteosarcoma and neuroblastoma has been one of the
great successes of paediatric oncology. Chemotherapy
has been effectively used in these diagnoses since the
1950s and now overall the majority of children with
these rare malignancies can be cured [66,67].
The incidence of Ewing’s sarcoma is approximately 10
cases per million for those aged 10–19 [68] and for
patients with localised disease the cure rate with com-
bined modality treatment is 71–94% [69] For patients
with metastatic disease at presentation approximately
30% will be cured using treatment based on the classical
cytotoxic chemotherapy drugs vincristine, doxorubicin,
ifosfamide, etoposide and busulphan and melphalan









































































































































































Figure 2 Gestational choriocarcinoma. Pre and post treatment CT scans of the chest showing multiple lung metastases and pulmonary
haemorrhage at diagnosis, 12 weeks post partum and a normal scan at completion of chemotherapy. The treatment graph shows the fall and
normalisation of the hCG level with combination chemotherapy treatment. The baby was unaffected by the illness, the patient has completed
treatment and gone on to have another healthy baby and has been cured of this rare malignancy.
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with a renal mass [70]. The use of combined modality
treatment including adjuvant chemotherapy has trans-
formed the prognosis of this rare condition, with pa-
tients with low stage disease having cure rates in excess
of 90% [71], whilst for the patients presenting with
metastatic disease chemotherapy treatment predomin-
antly using vincristine, dactinomycin, and doxorubicin
can result in cure rates of approaching 75% [34,72].
Osteosarcoma is a rare malignancy of childhood with
an estimated incidence of 4 cases per million between
the age of 0–24 [73]. The impact on chemotherapy in
this rare malignancy has been most marked in the
success of adjuvant therapy after surgery, however for
young patients with metastatic disease at presentation
chemotherapy treatment can be curative. A recentSEER overview indicates for young patients likely cure
rates of 80% for those presenting with localised disease,
65% for regional disease and 25% for patients with
metastases [73].
A further childhood cancer, neuroblastoma occurs
with an incidence of 10 cases per million children
[74]. Chemotherapy treatment using classical cyto-
toxic drugs including cyclophosphamide, doxorubicin,
carboplatin, etoposide produces a cure rate of 95% for
patients with good prognosis metastatic disease whilst
patients with localised disease have cure rates ap-
proaching 100% [35].
Historically, there has been debate regarding the cell
of origin of these malignancies, now there is an in-
creasing body of evidence that Ewing’s sarcoma, Wilms
tumours and osteosarcoma arise from mesenchymal
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neuroblastoma are the fetal neuroblast cells from the
neural crest [79,80]. These two cell types share signifi-
cant characteristics and it has been hypothesized that
the two types are actually two phenotypes of a com-
mon cell of origin [81].
Whilst the exact point of origin of the malignancies
remains uncertain and there is relatively little informa-
tion on the molecular pathways involved on both onco-
genesis and chemosensitivity, these tumors all appear to
arise from very primitive embryonal cells rather than
more differentiated mature cells.
In Ewings tumours there is the characteristic trans-
location EWS/ETS transformation which leads to the
transformation and the malignant phenotype [75]. More
recent publications have indicated that some of the key
molecular components in Ewings including EZH2 are
already present at gastrulation and can prevent cellular
differentiation [82]. Other recent work has suggested
that Ewings cells are derived from primordial streak
early mesoblasts [83] or neural crest derived stem cells
[84] which is in keeping with the original observations
from Ewing in 1921 [85].
In line with the theme that the other chemotherapy
curable malignancies have a close relationship with
unique genetic events, we can hypothesis that the
chemotherapy curability of the childhood malignancies
is linked to the close relationship of these cells with the
process of gastrulation. This process occurs in human
embryos at approximately day 16 when the single layer
of the blastocyst segregates into the three new germ layer
components of the ectoderm, mesoderm, and endoderm.
The ectoderm goes on to give rise to the skin, nerves
and neural crest cells, the mesoderm the bones, con-
nective tissues and urogenital system and the endo-
derm the gut and associated organs. During the process
of gastrulation there is cellular differentiation and a
dramatic increase in cell proliferation and growth. Dur-
ing this period there is a shortened cell cycle, which
may preclude cell cycle arrest and full DNA repair in
response to DNA damage. The process of gastrulation is
accompanied by an increased sensitivity to DNA damage,
with animal data indicating that the apoptotic response
to DNA damage can be up to 15 fold higher during
gastrulation than before or after the process [86].
Whilst there is little direct data to examine, we can
hypothesise that these cancers develop a malignant
phenotype during or soon after gastrulation and subse-
quently become frozen at their development point in a
similar fashion to the B cell malignancies and so still
retain some of the heightened apoptotic potential asso-
ciated with the gastrulation process. As a result in a simi-
lar situation to the patients with the other chemotherapy
curable malignancies these pro-apoptotic pressures arethen exploited therapeutically with the chemotherapy
induced DNA damage resulting in highly effective apop-
tosis and cell kill and the high cure rates observed.
Germ cell malignancies
Metastatic testicular cancer has been potentially curable
with chemotherapy since the 1960s [87] and modern
treatment now brings overall cure rates exceeding 80%
[88,89]. A routine example case of a patient cured of
intermediate risk testicular cancer is shown in Figure 3.
Similarly in women, advanced ovarian germ cell tu-
mours, whilst much rarer, are also effectively treated
with combination chemotherapy with overall cure rates
of approximately 80% [33]. In both diagnoses the most
widely used regimen of BEP comprises bleomycin, eto-
poside, and cisplatin, which are three conventional
cytotoxic drugs all introduced into routine care prior
to the mid-1980s [32,33].
The majority of testicular germ cell tumours arise
from areas of the pre-malignant precursor CIS [carcin-
oma in situ, also referred to as IGCNU or gonocytoma
in situ] [90,91]. This premalignant condition is believed
to arise from fetal gonocytes, with arrested development,
that persist inappropriately in the post natal testis rather
than making the standard progression to become quies-
cent pre-pubertal pre-spermatogonia [92]. The pathway to
the onset of malignancy and development of testicular
cancer is an area of relative scientific and biological com-
plexity [93]. The overall process of meiosis includes a
number of additional key complex genetic events; includ-
ing the repair of double stand DNA damage [94] and the
erasure of imprinting via genome wide demeythylation
[95], a situation that persist in CIS cells [96].
A simplified overview of the development of germ
cells and spermatogenesis can be summarised in the
following steps as shown in Figure 4. In the embryo at
approximately at 21–28 days gestation the primordial
germ cells arise from the proximal epiblast adjacent to
the extra-embryonic ectoderm [97]. During weeks 4–8,
the primordial germ cells migrate along the autonomic
nerve fibres to the genital ridge [98]. Up to this point,
the development processes are shared in both male and
female embryos, however in female embryos, the effect
of retinoic acid from the mesonephric duct at week 11,
induces the commencement of meiosis [99]. At this
point meiosis proceeds only through to the meiotic pro-
phase I with the cells becoming oocytes enclosed in
primordial follicles towards the end of the first trimester
[100]. In contrast in males at the start of gonadal devel-
opment at approximately 6 to 7 weeks gestation, the
action of sex-determining region Y (SRY) leads to Sertoli
cell differentiation and production of cytochrome p450
26B1 which degrades retinoic acid [101] which inhibits
the progression to meiosis. Additional newer data also
Figure 3 Advanced testicular cancer. Pre and post treatment CT scans of the chest showing multiple pulmonary lesions at diagnosis and
virtual resolution of the lesions by the time of completion of chemotherapy. The treatment graph shows the decline and normalisation of hCG
levels with BEP chemotherapy treatment. Nine years on the patient is in a complete remission, and is almost certainly cured. The lung lesions
resolved completely with longer follow up.
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pression of DMRT1 and STRA8 by the Sertoli cells may
also play a key role in this inhibition [102].
As a result of these processes in pre-pubertal males the
healthy gonocytes (pro-spermatogonia) are prevented from
entering meiosis and continue to divide mitotically and
then normally mature into pre-spermatogonia [103]. In
contrast in cases of CIS the gonocytes are held in devel-
opment as embryonic germ cells in the pre-pubertal
and adult testis and do not follow the normal progres-
sion to pre-spermatogonia [104].
In health the rise in testosterone levels at the onset of
puberty alters the balance between the inhibition and
promotion of meiosis and spermatogonia A start the
processes to produce sperm, dividing and giving rise to
the spermatogonia B and these then form the spermato-
cytes that produce the sperm.In the developmentally blocked CIS cells the onset of
puberty also leads to enhanced activity and the rising
risk of developing a malignant phenotype [105]. Whilst
historical scientific data suggested that CIS cells did not
arise from cells associated with meiosis [92] more recent
data indicates that the balance of the mitosis-meiosis
switch within the CIS cells is significantly altered at
puberty with pressure for both processes to occur.
Recent publications indicate that the meiosis inducing
proteins STRA8, SCP3 and DMC1 are present in CIS
cells whilst at the same time the meiosis inhibiting
NANOS2 and CYP26B1 regulators are also expressed
[102]. As a result there are concurrent pressures in the
cells for both mitosis and meiosis to be induced, a
process which helps the malignant phenotype develop
[106] but also fortunately leads to the developing malig-





















Figure 4 Spermatogenesis and cancer development. The normal and malignant development of testicular germ cells. The normal progression
from the primordial germ cell to the production of sperm is shown in the upper pathway. Testicular germ cell tumours develop via CIS from arrested
gonocytes that have an impaired mitosis/meiosis switch. Spermatocytic seminoma the malignancy arising from normal pre-meiotic spermatogonia is
characteristically chemotherapy resistant.
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healthy spermatogenesis and it is estimated that 75% of
sperm production undergoes apoptosis [47]. A number
of clinical observations lend support to the hypothesis
that it is the onset of meiosis in the CIS/tumour cells
which is linked to the development of the extreme
sensitivity to chemotherapy via DNA damage and the
induction of apoptosis, rather than their proximity to
the spermatogonial stem cells that drive the system.
Data from studies in which the testis has been exposed
to low doses of radiation demonstrate that the radiation
sensitivity of the differing stages of cells involved with
spermatogenesis varies significantly along the develop-
mental pathway. The cells that are most sensitive to
DNA damaging agents are the type B spermatogonia
that are undergoing going mitosis in preparation for
meiosis and the meiotic primary spermatocytes, whilst
the post meiosis spermatids and the spermatogonial
stem cells are much more resistant [107-109]. This
differential toxicity is supported from data from cancer
patients treated with chemotherapy or radiotherapy that
indicates that sperm counts fall significantly by 10 weeks
but do not reach azoospermia until 12 weeks post ex-
posure, a timescale in keeping with a production block
at the level of the type B spermatogonia [110-112].
In oncology patients treated with chemotherapy the
recovery of sperm production generally occurs as the
stem cell spermatogonia recover and restart the processof spermatogenesis and repopulate the intermediate
cells stages [109]. This process can take between 12 weeks
and 2 years dependent on the chemotherapy drugs
administered.
From this animal and clinical data it is apparent that
whilst the cells involved in preparing for and undergo-
ing meiosis are rapidly killed by DNA damaging agents,
their predecessors the spermatogonial stem cells are
not killed and these stem cells are with time able to
repopulate the whole production system. This finding
supports the hypothesis that the sensitivity to chemo-
therapy is not an intrinsic characteristic of the stem
cells themselves, but a characteristic acquired by the
cells whilst preparing for and undergoing meiosis.
Additional support to the hypothesis that the pre-
meiotic spermatogonial stem cells are resistant to
chemotherapy comes from recent data looking at the
cell of origin of the chemotherapy resistant malignancy
spermatocytic seminoma. This rare malignancy is char-
acterised by a high degree of resistance to chemother-
apy [113] and recent work has confirmed that the cell
of origin of this malignancy is the spermatogonial stem
cell [114]. The spermatogonial stem cells have not
made the progression to meiosis and the malignant
cells arising from them show much greater resistance
to chemotherapy compared to either healthy sperma-
togonia cells undergoing meiosis and or to the CIS
derived testicular germ cell tumours.
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Malignant ovarian germ cell tumors (mOGCT) are rare, oc-
curring at less than 10% the rate of testicular cancer with a
peak incidence of approximately 1 case per 100,000 women
aged 15–19 [115]. The most frequent pathological type is
dysgerminoma, which is similar to seminoma in men whilst
non-dysgerminomas have a similar range of pathologies as
non-seminomatous germ cell tumours have in men [116].
Whilst early stage ovarian germ cell tumours can be
managed by surgery and surveillance based on tumour
markers and imaging [117], stage II and more advanced
tumors are treated with combination chemotherapy treat-
ment [118]. Similarly to testicular cancer, chemotherapy
with cisplatin based regimens such as BEP and POMB-
ACE can bring dramatic responses to treatment and cure is
the most likely outcome even for patients with widespread
metastatic disease [33]. As an example of the high degree
of chemosensitivity in this diagnosis the imaging of aFigure 5 Ovarian germ cell tumour. Pre and post treatment CT scans of
abdomen and pelvis prior to chemotherapy treatment. The residual mass i
necrotic material. The treatment graph shows the tumour produced hCG le
of pituitary hCG production secondary to amenorrhea resolved with the repatient presenting with very large mOGCT and cured with
chemotherapy is demonstrated in Figure 5.
In women the development pathways of oocytes and the
risks and mechanisms for malignant change have many
similarities to testicular germ cell tumours in men. In the
fetal ovary the germ cells under the influence of retinoic
acid commence meiosis and become fixed in meiotic pro-
phase 1 with the oocytes going on to form the primordial
follicles [119]. In health the oocytes are held at the stage of
the first meiotic division, which took place in the develop-
ing fetus, until ovulation a number of decades later, when
they complete the first meiotic division and then again stop
in metaphase in the second meiotic division at the time of
the release of the egg from the ovary. If the egg is fertilised
there is then completion of the second meiotic division and
the release of the polar body after fertilisation [101].
Whilst in testicular germ cell tumours, the cell of origin
of the malignancy is CIS, in mOGCT the likely cell ofthe pelvis showing an enormous ovarian germ cell tumour filling the
n the post treatment scan was resected and was composed entirely of
vel falling to normal within the first month of treatment. The low level
starting of menstruation 12 months after completion of treatment.
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containing fetal germ cells mixed with immature Sertoli
and granulosa cells and have many similarities to testicular
CIS cells [120]. Gonadoblastomas are only found excep-
tionally rarely in healthy ovaries with their development
linked to Sertoli cell underdevelopment and an environ-
mental imbalance in the development of the maturing
ovary but are more common in women with disorders
of sex development [121]. It is postulated that some of
the germ cells within the gonadoblastoma, may have
postponement or failure of the onset of meiosis and
these cells could continue to divide mitotically [122].
The exact pathways for the malignant transformation in
gonadoblastoma are complex but it is apparent that these
cells retain their fetal phenotype and are susceptible to the
development of malignancy [123]. In disorders of sex
development patients with dysgenetic gonads and Y
chromosomes, the activity of the TSPY gene [testis specific
protein Y] in the gonadoblastoma locus appears to act as
an oncogene [122]. Of interest in the healthy testis this
protein is expressed in meiotic prophase I and plays a role
in chromatin organisation and the progression of the
prophase I and meiotic divisions [124,125].
In women with an XX genotype, ovarian germ cell tu-
mors are rare and the exact process of oncogenesis in the
absence of Y chromosome proteins is less clear. However
in that gonadoblastoma cells are immature germ cells with
a fetal phenotype in an adult ovary it is possible that the
route to both malignant transformation and the extreme
chemotherapy sensitivity seen in mOGCT could have simi-
larities to the disruption of the meiotic mitotic switch seen
as in CIS and testicular germ cell tumours [123].
The outlook for women treated for mOGCT is
positive with cure rates in excess of 80%. Whilst the
chemotherapy treatment is usually able to kill all of the
tumour cells, however the healthy oocytes are mainly un-
damaged and the large majority of women usually recover
their menstrual cycle after chemotherapy [126,127].
Overall in mOGCT it appears that malignant cells
that are naturally highly sensitive to DNA damage arise
from the gonadoblastoma, whilst the cells in the ovarian
follicles that are in a halted meiosis (for decades) are
relatively resistant. This finding again lends support
to the hypothesis that it is the onset of active meiosis,
rather than the relationship with the stem cell that is
linked to the chemotherapy sensitivity and curability.
B cell malignancies
The complex natural history of B cell development involves
progression from the haematopoietic stem cell (HSC)
through to final maturity via a number of key stages includ-
ing pre B cell, marginal zone, germinal centre cell, mature
B cell and plasma cell as shown in Figure 6. The malignan-
cies that arise at differing points along this developmenthave significantly different levels of response and cura-
bility with chemotherapy treatment. Acute lymphoblastic
leukemia (ALL), diffuse large B cell lymphoma, Hodgkin’s
lymphoma and Burkitt’s lymphoma are all routinely curable,
whilst acute undifferentiated leukemia, chronic lymphocytic
leukemia (CLL), mantle cell lymphoma, follicular lymphoma
and myeloma are generally incurable with chemotherapy.
The variation in chemotherapy curability across the
malignancies arising during B cell development shows a
relatively low cure rate in the malignancy arising from
the stem cells, but significant rises with some of the later
cell types. This suggests that the overwhelming sensitiv-
ity to chemotherapy is a characteristic that is not present
in the native haematopoietic stem cells, but is acquired
for ALL, lost for marginal zone and mantle lymphomas,
reacquired for diffuse large B cell lymphoma and
Hodgkin’s lymphoma and then finally lost again later in B
cell development. This pattern suggests that processes
aside from the proximity to the stem cell, or the rate of
cell growth, are responsible for the chemotherapy curabi-
lity rather than the chemotherapy curability being simply
as a result of developmental proximity of these malignan-
cies to the stem cells themselves or the rate of growth.
It has previously been described how the onset of the
malignant phenotype can freeze B cells at a point in their de-
velopment process leading to the wide range of B cell malig-
nancies from acute undifferentiated leukemia to myeloma
[24,25]. From a clinical perspective it would also appear that
the varying B cell malignancies of acute undifferentiated
leukemia all the way through to myeloma also retain their
then current natural level of apoptotic potential associated
with the unique genetic processes of; VDJ rearrangement,
somatic hypermutation and class switching that were occur-
ring at the time of malignant transformation [27]. The de-
gree of apoptotic sensitivity that is associated with these
processes appears to remain in place in these malignancies,
despite the numerous cell divisions and passage of poten-
tially years from the onset of malignancy in a single cell
through to the eventual time of diagnosis and treatment.
A brief overview of the natural history, development and
genetic events in B cell development
B cell development commences with the hematopoietic
stem cells that develop into pro B cells in the bone
marrow. In the pro B cell the processes of VDJ re-
arrangement of the immunoglobulin heavy chain gene
and VJ rearrangement of the light chain genes take
place. These processes involves double strand DNA
breaks in the immunoglobulin genes by the RAG
proteins, at areas linked to the recombination signal
sequences [128,129], which are then repaired by DNA
repair mechanisms including non-homologous end
joining (NHEJ) [130,131]. However the process recom-
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Figure 6 Genetic events and chemotherapy sensitivity in malignancies derived from the haematological stem cells. The curability with
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recombine and make a functional B cell receptor are
lost via apoptosis [132,133].
The process of VDJ rearrangement activity in B cells
commences at low levels in HSC and progenitor B cells
and then has a peak of activity in pro B cells, declines in
pre B cells and is absent in mature B cells [134]. Of
interest the activity of the RAG systems that produce
VDJ rearrangement starts activity significantly prior to
the VDJ rearrangement events [135] and is not limited
just to the haematopoetic stem cells destined to become
B and T cells. There is also significantly VDJ activity
occurring early in the development of hematopoietic
stem cell that go on to the pathway of myeloid differen-
tiation with VDJ rearrangement present in many cases of
AML [136] and also occurring later in development
prior to acute lymphoid blast crisis in CML [137].
B cells that have successfully recombined their im-
munoglobulin genes and have a functional B cell recep-
tor turn off the VDJ system and leave the bone marrow
as mature naïve B cells [138,139], whilst those that have
an unsuccessful rearrangement perish by neglect and
undergo apoptosis [140]. The next stage in B cell devel-
opment is antigenic contact that triggers the germinal
centre reaction that includes the two additional DNA
modification steps of somatic hypermutation, followed
by immunoglobulin class switching.These processes are mediated by activation induced
cytidine deaminase (AID) that produces mutations,
insertions and deletions within the immunoglobulin
hypervariable regions during somatic hypermutation
[141]. Following somatic hypermutation the germinal
B cell then undergoes class switching again using AID
to cut the DNA and the NHEJ enzyme complex to
repair the breaks [142,143].
These complexes processes of immunoglobulin gene
VDJ rearrangement and somatic hypermutation are
recognised to be associated with the induction of lym-
phomagenesis, with VDJ rearrangements particularly
linked to malignancy associated translocations including t
[8,14], t[14:18] and BCL2 [144-147], whilst somatic
hypermutation is linked to the myc translocations seen
in Burkitt’s lymphoma [148]. Despite this significant risk
of oncogenesis occurring from immunoglobulin gene
genetic rearrangement mechanisms, it appears from an
evolutionary viewpoint, that the benefits of an adaptive
immune system appear to outweigh the risks of malig-
nancy associated with the process [149].
Whilst the exact timeline and cell of origin of some
types of B cell malignancy are yet to be fully confirmed,
there is a general consensus on most of the key types.
The relationship between the cell of origin, the unique
genetic processes and chemotherapy curability is dem-
onstrated in Table 1 and discussed below.
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malignancies
During cytotoxic chemotherapy treatment the early
progenitor stage haemopoietic stem cells are signifi-
cantly affected by treatment but with standard dose
chemotherapy these cells are not killed off and after an
interval, stem cell function is fully recovered.
Malignancies arising from the primitive haemopoietic
stem cells are very rare and relatively poorly charac-
terised. Acute undifferentiated leukemia is believed to
arise from the undifferentiated haematopoietic stem cells
but a number of studies which have examined the status
of the immunoglobulin and T cell receptor genes in this
malignancy, indicate that a significant number of these
cases have already commenced VDJ rearrangement [150].
However, overall less than 50% of cases have started VDJ
rearrangement and a smaller proportion T cell receptor V
[D]J rearrangement and the majority of cases of acute
undifferentiated leukemia still have germ line unrecom-
bined VDJ genes [150].
Acute undifferentiated leukemia arising from the
haemopoietic stem cells has a poor prognosis despite
modern treatment with intensive chemotherapy. Over-
all long term survival rates of approximately 20% have
been reported [150] and the recent US SEER data indi-
cates a 5 year survival rates of 65% for children, 35% for
adults aged 20–39 but only 3% for those aged 60+ [151].
Taken together the cure rates from the malignancies that
actually arise from the haemopoietic stem cells, are
significantly lower than for the B and T cell acute
lymphoblastic leukemias that arise at the next develop-
ment stage, where the process of VDJ rearrangement is
more fully active.
VDJ rearrangement associated malignancies
In contrast to acute undifferentiated leukemia, B cell
ALL arises from pro B cells that are undergoing VDJ
rearrangement in the bone marrow but are yet to
proceed on to somatic hypermutation [133,152-154].
The treatment for B ALL patients centres on the use of
classical cytotoxic chemotherapy drugs used with a high
degree of dose intensity. The most frequently used regi-
mens include dexamethasone, vincristine, asparaginase
and daunorubicin, and the successful treatment of child-
hood B ALL has been one of the great success stories of
malignant haematology [155]. Recent data from the US
SEER series indicates that the cure rates range from
>90% in children and teenagers to approximately 50%
for those occurring in adults but falling to only 10% in
the elderly [151].
The prognosis of B ALL diagnosis is significantly bet-
ter than for those with more primitive diagnosis of acute
undifferentiated leukemia that arises from the haemo-
poietic stem cells, the cell type preceding it in B celldevelopment. This finding showing an increase in cure
rates with differentiation is in keeping with the impact
of the onset of VDJ rearrangement and contrary to that
expected if proximity to stem cell function is the key
contributor to chemotherapy curability.
Of interest the cure rates of B ALL vary distinctly with
the age of the patient, ranging from near uniform cure
in children down to only 10% in elderly patients [151].
Traditionally this decline with age has been ascribed
to differing intensity of chemotherapy treatments, un-
favourable mutations and worse prognosis presentation
[156,157]. However, in line with the hypothesis that the
overall sensitivity to chemotherapy in B ALL is a product
of the mechanisms and associated apoptotic potential of
VDJ rearrangement, it is also possible that the reduction
in chemotherapy sensitivity and hence cure rates is
related to the major decline in VDJ recombinase activity
and potentially related pro-apoptotic potential seen in
early B cells with increasing patient age. Recent data has
demonstrated that the activity of the B cell VDJ system
changes significantly with the age of the patients, with
the overall activity levels of RAG1 and other key com-
ponents falling dramatically from toddlers to middle
aged adults giving a similar pattern to the fall in B ALL
cure rates with increasing age [158]. Alongside this
an number of key B cell signalling and B cell receptor
proteins are expressed at only around 20% of the child-
hood level in adults [159].
Post VDJ rearrangement, pre somatic hypermutation
associated malignancies
The malignancies that arise from B cells that have com-
pleted VDJ rearrangement but not undergone somatic
hypermutation include mantle cell lymphoma and chronic
lymphocytic leukemia [CLL]. In these diagnoses the ma-
jority of cases contain immunoglobulin genes that have
successfully undergone VDJ rearrangement but not
commenced somatic hypermutation [160,161]. In both
of these diagnoses chemotherapy treatment brings
major responses and remissions but they are not cur-
rently regarded as being curable.
Of interest approximately 20% of cases of mantle zone
lymphoma and 50% of CLL have a degree of somatic
hypermutation of their immunoglobulin genes and these
cases are linked to a significant improvement in re-
sponse to but not cure with chemotherapy treatment
[162,163]. In mantle cell lymphoma the impact on the
hyper-mutated status of the variable domain is signifi-
cant as those with mutated genes have a 5 year event
free survival of 75% vs only 23% for those with classical
unmutated Mantle cell lymphoma [164]. In CLL an early
study demonstrated dramatically divergent median pa-
tient survival dependent on the IGH mutation status of
95 months with unmutated IGH genes and 293 months
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using ZAP70 expression as a surrogate for IGH muta-
tional status indicate similar positive results with patients
with mutated IGH receiving more modern therapies
[165]. At the molecular level it is apparent that in the in
the cases of CLL that have evidence of SHM activity and
mutated variable regions, serial analysis from CLL patients
suggests that the SHM process is no longer on going
during the clinical stages of the diagnosis [166].
Somatic hypermutation associated malignancies
The processes of somatic hypermutation takes place pre-
dominantly within the lymph node germinal centre and
involves the action of activation induced cytidine deami-
nase [AID] on cells that have a successfully recombined
IGH gene [167]. The action of AID is focused predomin-
antly on the variable regions of the immunoglobulin
genes and it is estimated that the AID leads to a muta-
tion rate in the variable regions that is approximately 1
million times higher than would occur by spontaneous
mutation alone [168]. The process of somatic hyper-
mutation carries two risks to the cell, firstly of causing
inappropriate changes to the immunoglobulin gene that
lead to ineffective B cell receptor production and these
cells are generally removed by apoptosis. The second
risk is that the somatic hypermutation activity is not
completely restricted to the immunoglobulin variable
genes and can cause unwanted and potentially hazard-
ous mutations at other sites, increasing the risk of lym-
pomagenesis [148].
In contrast to the non-chemotherapy curability of B
cell malignancies arising in cells that have completed
VDJ rearrangement but not effectively proceeded to
somatic hypermutation, three B cell malignancies de-
rived from B cells whilst they are undergoing somatic
hypermutation all have routine high cure rates with
combination chemotherapy.
Genetic analysis indicates that the diagnosis of diffuse
large B cell lymphoma DLBCL contains at least 3 major
subtypes, germinal centre, activated B cell and primary
mediastinal that can be distinguished by their genetic
signatures, cell of origin and also by their proximity to the
key genetic events in B cell development [169,170]. The
impact of the cell of origin of the lymphoma in terms of
response and cure rate to first line and second line chemo
therapy treatment has been clearly demonstrated, with
overall cure rates in germinal centre DLBCL of approxi-
mately 80% compared to only 50% in the activated B cell
form [170,171]. In the germinal centre DLBCL it is
apparent that the somatic hypermutation process has
not only commenced but remains active during the
natural history of the malignancy as demonstrated with
serial biopsies show the evolution of the changes in
immunoglobulin gene hypervariable regions [172].Whilst DLBCL is potentially curable in all age groups,
the cure rates for DLBCL decline significantly with increas-
ing patient’s age in a parallel fashion as seen in B-ALL. At
the age of 15–49 the reported cure rate is approximately
75%, but falls to 52% for those aged 75 and over [173] In a
similar process to that seen in VDJ recombinase activity
and B ALL cure rates, the level of activity of SMH system
has been demonstrated to fall dramatically in B cells with
increasing patient age and this may be linked to the fall in
the cure rates of DLBCL seen in older patients [174].
Burkitt’s lymphoma appears to arise in germinal centre
B cells that have undergone somatic hypermutation of
the VH genes and is characterised by translocation of
the c-myc oncogene [175]. There is a difference in the
degree of somatic hypermutation and antigenic selection
with higher levels seen in the endemic rather than the
related sporadic forms [176]. Data indicates that in the
sporadic form of Burkitt’s lymphoma the cells are early
centroblasts that normally would be proceeding with
additional somatic hypermutation but are blocked by the
onset of the malignant process. In contrast in the en-
demic or EBV associated form, the cells have completed
somatic hypermutation and starting to mature [176] and
the EBV infection and the expression of EBNA-1 acts as
an inhibitor of apoptosis [177].
The overall cure rate in Burkitt’s lymphoma with in-
tensive combination chemotherapy such as CODOX-M/
IVAC (cyclophosphamide, vincristine, doxorubicin, and
high-dose methotrexate, alternating with ifosfamide, eto-
poside, and cytarabine) with Rituximab is in the region
of 77–85% for adults [43].
In Hodgkin’s lymphoma the actual malignant cells make
up only a very small proportion of the cell mass and
studies on the accurate assessment of the cells of origin
and key genetic events and mutations has lagged behind
that of non-Hodgkin’s lymphoma. The cells of origin of
classical Hodgkin’s disease is confirmed as germinal
centre B cells which have completed VDJ rearrange-
ment, with no ongoing recombinase activity [178] and
have also undergone somatic hypermutation [179,180].
However it is apparent that these cells are unable to
make functional immunoglobulin [179]. Normally in
this situation failed germinal centre B cells would be
destined to undergo natural apoptosis [181]. However
in Hodgkin’s lymphoma these cells with these ‘crippling’
mutations of the immunoglobulin chain are generally
viewed as failed germinal centre B Cells that are pre-
apoptotic but prevented from progressing to an apop-
totic death by EBV infection [181,182] It may be that
the loss of the classical B cell phenotype seen in Hodgkin’s
disease is a result of the cell moving part of the way down
the apoptotic pathways but with the completion of the
normal apoptotic pathway blocked as a result of EBV
infection [183,184].
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Hodgkin’s lymphoma Hodgkin’s is ABVD, which com-
prises doxorubicin, bleomycin, vinblastine and dacar-
bazine, which are all old classical chemotherapy drugs
[41]. Overall the disease has a chemotherapy cure rate
of approximately 80% [185] and it would appear that
the addition of the chemotherapy induced DNA damage
is sufficient to alter the DNA repair/apoptosis balance
to fully effective apoptosis and in doing so overcome
the obstacle of the EBV driven anti-apoptotic signaling.
Post DNA manipulation B cell malignancies
After the completion of somatic hypermutation and class
switching, B cells move towards exiting the germinal
centre and move through the lymphoplasmacytic diffe-
rentiation to become an antibody secreting plasma cell.
Each of the malignancies arising after this stage in B cell
development, whilst frequently responsive to chemother-
apy nearly all cases are not curable with chemotherapy.
The most common of the post VDJ post somatic hyper-
mutation malignancies is follicular lymphoma. Classically
the cell of origin for a follicular NHL is considered to be
the centrocyte of the germinal centre and involves a cell
that has completed somatic hypermutation and class
switching and is set on the next stage of development.
Clinically follicular lymphoma is characterised by a slow
pattern of growth and excellent response to chemotherapy
treatment but chemotherapy does not result in cure [186].
In terms of the unique genetic events, follicular lymph-
oma is demonstrated to carry rearranged immunoglobulin
genes that have undergone somatic hypermutation. Whilst
in germinal centre DLBCL the process of somatic hyper-
mutation appears to remain ongoing and active in the
malignant cells [172,187], in follicular lymphoma the
clinical data from repeat analysis of immunoglobulin
heavy chain gene sequences through the natural history
indicates that whilst AID is still expressed there is little
or no on-going somatic hypermutation in follicular
lymphoma cells, [188-190]. This divergent finding re-
garding the ongoing activity of the somatic hypermuta-
tion process between diffuse large B cell lymphoma and
follicular lymphoma appears to coincide with the differ-
ing expectations of the outcome of chemotherapy treat-
ment between these two similar malignancies.
The other post somatic hypermutation B cell malignan-
cies include activated B cell diffuse large B cell lymphoma,
MALT lymphoma, lymphplasmacytic lymphoma and mye-
loma. These malignancies vary significantly in their natural
history and response to chemotherapy treatment.
Of these activated B cell DLBCL lymphoma has a sig-
nificant cure rate with chemotherapy with approxi-
mately 40% of patients cured compared to 75% of these
with germinal centre DLBCL [170]. In the activated B
cell form it is apparent that the somatic hypermutationprocess is generally completed and the activity of AID
has declined significantly but is still present but there is
no ongoing somatic hypermutation occurring [172,190].
The role of the apoptosis associated with somatic hyper-
mutation is less well clarified and we could hypothesise
that the significant but lower cure rates seen in activated B
cell DLBLC is the result of some of the somatic hyper-
mutation associated apoptotic pathways having some
appreciable residual activity in a proportion of cases.
Nodular lymphocyte predominant Hodgkin’s lymphoma
(NLPHL) is a more recently described diagnosis that
makes up approximately 5% of Hodgkin’s disease cases
and has a similar morphology to classical Hodgkin’s but
differs with a lack of expression of CD15 and CD30 [191].
In NLPHL the immunoglobulin genes have undergone
VDJ rearrangement and somatic hypermutation and
in contrast to classical Hodgkin’s Lymphoma the L and
P cells of NLPHL frequently express surface immu-
noglobulin [191,192].
The chemotherapy management of NLPHL is usually
with ABVD and for patients with advanced disease chemo-
therapy the overall 10 year disease free survival is approxi-
mately 70% which is similar to contemporary results for
patients with classical Hodgkin’s lymphoma [193].
In contrast to classical Hodgkin’s lymphoma in which
the B cells have completed somatic hypermutation and
express little AID activity, in NLPHL there remains
significant ongoing AID and SHM activity [194,195].
Whilst classical Hodgkin’s lymphoma appears to be a
failed B cell that is prevented from undergoing natural
apoptosis by EBV infection, it is likely that the marked
chemosensitivity of NHLPL, which characteristically
EBV negative [196] stems from the same route as that
of DLBCL with ongoing AID activity and the sustained
presence of the pro-apoptotic pathways associated with
the somatic hypermutation process.MALT and lymphoplasmacytic lymphoma
MALT lymphomas have undergone VDJ rearrangement
and completed somatic hypermutation of their immuno-
globulin genes [197] and have a relatively indolent nat-
ural history. Chemotherapy treatment with the regimens
used in follicular lymphoma frequently brings long lived
responses but the majority of cases if followed suffi-
ciently long will relapse [198].
Similarly lymphoplasmacytic lymphoma (Waldenstroms
macroglobulinaemia) arises from mature B cells that have
rearranged VH genes, have undergone somatic hyper-
mutation [199] but have failed to complete class switching
[200-202] This malignancy also has a good response rate
to chemotherapy but is not chemotherapy curable and has
a shorter natural history that follicular NHL or MALT
with a median survival of approximately 8 years [203].
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Hairy cell leukemia [HCL] is a rare B cell malignancy that
is dramatically responsive to DNA damaging chemother-
apy. The modern standard of care is chemotherapy with
cladribine and a single cycle of therapy brings a complete
response rate of 91% and an average response duration of
98 months [204,205]. However given sufficient follow up,
nearly all patients will relapse and require additional ther-
apy. The cell of origin of hairy cell leukemia appears to be
a mature B cell that has arrested at the point of isotype
switching and individual clones of hairy cell leukemia
frequently show staining for more than one isotype of
surface immunoglobulin [206]. In HCL there appears to
be a degree of ongoing AID expression but there is rela-
tively little clonal variation indicating that the functional
SHM process has halted [207].
More recent data has indicated that the BRAF protein
that is involved in signal transduction from the B cell
receptor has a characteristic V[600]E mutation in nearly
all cases of HCL a finding that is not present in any
other lymphoid malignancy [208]. This mutation results
in constitutive activation of the MEK-ERK pathway that
results in a strong survival signal and avoidance of
apoptosis [209,210]. As a result it could be postulated
that hairy cell leukemia shares a similar scenario to
Hodgkin’s lymphoma and ALK+ T cell lymphoma that it
is a cell that is blocked from natural apoptosis by the pres-
ence of in this case the BRAF V[600]E mutation. The
dramatic response to chemotherapy suggests that the
DNA damage can shift the balance to highly effective
apoptosis, using the mechanisms that are still partially in
place linked to the AID activity that is on-going, albeit
at a lower level than is present in DLBCL [206,211].
In keeping with other B cell malignancies, hairy cell
leukemia has a small subgroup with unmutated im-
munoglobulin genes. These cases make up less than 5%
of the cases of hairy cell leukemia and have a very poor
response to chemotherapy treatment and can be refrac-
tory to first line cladribine therapy [212].
Myeloma
Similarly to the other malignancies of mature B cells,
genetic analysis indicates that the malignant cells in
myeloma have completed somatic hypermutation and
have no ongoing genetic activity [213-215]. The modern
treatment of myeloma centres on the use of proteasome
inhibitors that has transformed the response rates and
median survival but hasn’t changed the incurable nature
of the malignancy. Data from and early study with the
addition of Bortezomib to cytotoxic chemotherapy indi-
cates this drug has improved complete response rates
from 4% to 30% and first line progression free survival
14 months to 18.3 months but that myeloma remains an
incurable malignancy [216].T cell malignancies
Despite the similar numbers of B cells and T cells, T cell
malignancies are relatively rare comprising approxi-
mately 10% of the total cases of lymphoma [217]. In
contrast to the three processes of VDJ rearrangement,
somatic hypermutation and class switching occurring in
B cells, T cells have a simpler pattern of genetic activity
to achieve their variation in antigenic recognition with
only rearrangement of the V and J regions in the TCR
alpha chain whilst the TCR beta has the fuller rearrange-
ment of the VDJ components similarly to a B cell [130].
In a parallel fashion to that seen in B cell malignancies
the rise in chemotherapy curability coincides with the
onset of V[D]J rearrangements in the T cell receptor
genes. As discussed previously the rare cases of acute
undifferentiated leukemia that arise from the primitive
haematopoietic stem cells, that are yet to undergo effect-
ive immunoglobulin gene or TCR VDJ rearrangement
the chemotherapy cure rates are relatively low. In con-
trast in acute T cell ALL the V[D]J genes are recombined
in nearly 100% of cases [218] and this malignancy has a
high cure rate similar to B ALL with 70% for those aged
5–19, 50% aged 20–39 and 20% aged 60 and above
[151]. Of interest a recently identified poor prognosis
sub group of T ALL has been demonstrated to be T cell
receptor negative and is likely to arise prior to the VDJ
process becoming fully active [219] and hence has much
lower apoptotic potential than T ALL arising during VDJ
rearrangement.
Of all the T cell malignancies arising later than T ALL in
development, the ALK + ve anaplastic large cell lymphoma
is the only one with a significant chemotherapy cure rate.
The ALK + ve form of anaplastic large cell lymphoma is
usually treated with CHOP chemotherapy and long term
survival rates of 70–86% are reported [44,220].
This diagnosis has a similar natural history to classical
Hodgkin’s lymphoma. ALK + ve large cell lymphoma
arise from T cells that have undergone V[D]J recom-
bination but have failed to produce a functional T cell
receptor [221]. Usually these cells would be destined to
undergo natural apoptosis in a similar manner to the
failed B cells in Hodgkin’s lymphoma [222]. However in
the ALK + ve large cell lymphoma the cells have a t[2;5]
[p23;q35] reciprocal translocation that activates the ana-
plastic lymphoma kinase gene that leads to abnormal
proliferation and resistance to apoptosis [223,224]. As a
result the malignant cells are balanced between the pres-
sures and pathways for apoptosis and proliferation and
the introduction of radiation or chemotherapy induced
DNA damage can successfully tip the balance to apop-
tosis, cell death and frequently curative treatment.
The rarer form of ALK –ve large cell lymphoma also
has clonally rearranged T cell receptor VDJ genes and
similarly to ALK + ve large cell lymphoma does not have
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ALK -ve cells do not undergo natural apoptosis as a
result of the failed TCR gene recombination but of inter-
est the 5 year overall survival for ALK –ve T cell lymph-
oma at 49%, whilst significantly lower than that of ALK +
VE [70%] is significantly higher than the 32% reported
other peripheral T cell malignancies [225].
There are a wide range of other malignancies arising
from mature, post V[D]J] T cells, that correspond to
other points on the cells development. The natural history
and response to chemotherapy of these malignancies in-
cluding peripheral T cell lymphoma, angioimmunoblastic
lymphoma and adult T cell leukemia/lymphoma varies
significantly but they each have a poor prognosis with
modest 5 year survival rates and no significant cure
rates [226].
Myeloid malignancies
Acute myeloid leukemia [AML]
AML arises from myeloblast cells, that are derived from
haematopoietic stem cells via the myeloid stem cells and
there are approximately 3.7 cases per 100,000 per year
with incidence peaks in young children and older adults
[227]. The current standard of treatment employs the
classical cytotoxic chemotherapy drugs cytarabine and
daunorubicin and recent treatment series indicate an
overall cure rate of approximately 40% [40].
Superficially it might appear that AML is an exception
to the hypothesis on the importance of the unique
genetic events on chemotherapy curability, as myeloid
cell development whilst complex, does not require any
DNA manipulations. However as previously discussed,
the process of VDJ rearrangement that occurs during
lymphoid development frequently starts in the common
haematopoetic stem cell at a point prior to their differenti-
ation into lymphoid or myeloid stem cells. A number of
studies have confirmed that these unique genetic events of
VDJ rearrangement that are associated with B cell and T
cell development are occurring at significant levels in the
cells that develop into AML. In studies of AML, genetic
analysis indicates that the immunoglobulin heavy chains
genes have undergone VDJ rearrangement in 40–50% of
cases and that the expression of the VDJ recombinase
associated proteins RAG1 and RAG2 was also detectable
in approximately 50% of cases [136,228]. More recent data
confirms that VDJ recombination had occurred in the
AML myeloblasts of 50% of patients and that there was
also limited evidence of somatic hypermutation occurring
[229]. In keeping with the observation that VDJ rearran-
gement is a common event in haematopoietic stem cells
destined to proceed towards myeloid differentiation,
evidence of significant level of earlier VDJ recombination
but not somatic hypermutation are found in monocytes
and neutrophils from healthy donors [229]. It is possiblethat this presence of VDJ activity and the associated pro-
apoptotic processes may be linked to the high degree of
sensitivity in the production of these cells seen during
chemotherapy treatment.
Overall the data is limited on the impact of the com-
pletion of these immunoglobulin gene VDJ changes on
prognosis and response to chemotherapy and it may be
that cells that have completed the IGH VDJ process are
less sensitive to induction of apoptosis than those with the
malignant process occurring whilst VDJ is still occurring
[136,228,230]. However the observation that overall AML
has a significantly higher cure rate than acute undifferenti-
ated leukemia suggests that the processes that lead to the
high cure rates in B ALL and T ALL may share a common
pathway with the VDJ rearrangements pathways seen in
all 3 types of cell.Chronic myeloid leukemia [CML]
CML is a malignancy of the haematopoietic stem cells
and the BCR/ABL translocation is the source of the
malignant phenotype and transformation [231,232]. The
incidence is approximately 1–2 cases per 100,000 and
the peak incidence is in patients in their 60s.
The malignant cells early in the natural history of
CML during the chronic phase, have unrecombined VDJ
genes but by the time of entry into lymphoid blast crisis
the VDJ regions have become rearranged in the majority
of cases. In contrast in myeloid transformation of CML,
VDJ rearrangement is rare [137,233].
In studies of chemotherapy treatment of the lymphoid
blast crisis, performed prior to the introduction of Imatinib,
patients were not cured but had a better response to
chemotherapy [median survival 12 months vs 4.7 months]
than those with non-lymphoid blasts, with the results sug-
gesting that the processes associated with VDJ improve the
response to chemotherapy [234].
In contrast to other malignancies, including B ALL
and T ALL and AML, which arise in cells around the
time of VDJ rearrangement, CML in lymphoid blast
crisis is not chemotherapy curable. This divergent out-
come compared to the acute leukemias may reflect two
key differing elements of the CML lymphoid blast cells.
The first significant difference between CML and the
acute leukemias is the timing of the VDJ rearrangement
and the onset of the malignant phenotype. In the acute
leukemias the malignant transformation occurs early in
the cells development and concurrently with the VDJ
rearrangement and the cells retains the apoptotic sensi-
tivity of these cells. In contrast in CML the VDJ re-
arrangement occurs much later in the natural history of
the malignancy, often many years after the establish-
ment of the malignant phenotype by the BCR/ABL
translocation.
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translocation on inhibiting apoptosis. The major im-
pact of this protein on inhibiting apoptosis is seen in
studies where BCR/ABL has been transfected into chemo-
therapy sensitive cells lines leading to high levels drug re-
sistance [235]. As a result the presence of the BCR/ABL
activity may be sufficient to override the apoptotic sensi-
tivity normally seen with active VDJ rearrangement.
Other myeloid malignancies
Other myeloid malignancies, including myelodysplastic
syndrome, atypical CML, and chronic myelomonocytic
leukemia are characterised by poor response to chemo-
therapy. Analysis of the immunoglobulin and T cell re-
ceptor genes in myelofibrosis indicates that the vast
majority of cases have unrearranged germ line genes
[236,237]. Similarly in acute myelomonocytic leukemia
and acute monoblastic leukemia immunoglobulin gene
rearrangements are not detected [238] and these malig-
nancies have relatively poor responses to chemotherapy
and low cure rates [239].
Summary and therapeutic implications
The historical explanations for chemotherapy sensitivity
and resistance usually include the concepts of rates of
growth, mathematical risks of the development of re-
sistance, drug efflux pumps and changes in DNA repair
mechanisms. For many oncologists these hypotheses
appear to be potentially at odds with the clinical data,
which sees patients with a limited range of malignancies
routinely cured but other fast growing malignancies in-
cluding small cell lung cancer and epithelial ovarian
cancer responding dramatically to chemotherapy, often
achieving a complete remission but uniformly relapsing.
In this review we have examined an additional key
factor that appears to impact greatly on the sensitivity
and curability of malignancies with chemotherapy treat-
ment; the relationship of the cell of origin of the malig-
nancy to the unique genetic processes of nuclear fusion,
gastrulation, meiosis, VDJ rearrangement and somatic
hypermutation. Each of the disseminated malignancies
that are currently routinely curable with cytotoxic chemo-
therapy arises from cells with naturally occurring height-
ened apoptotic potential linked to the unique genetic
events, whilst all other metastatic malignancies that
arise from cells that are not involved in these processes
are not chemotherapy curable.
Whilst it is clear that the historical explanations for
chemotherapy resistance retain an important role in the
degree of sensitivity and the resistance of some cases of
the chemotherapy curable diagnoses to treatment, we
would hypothesis that what determines the overall de-
gree of sensitivity is the relationship with these unique
genetic events.The clinical applications of technology to overcome
chemotherapy resistance, whether by effecting drug efflux
pumps, or replacing mutated apoptotic pathways proteins,
such as p53 have shown only modest activity and are these
do not form part of routine clinical care [240].
There has been enormous endeavour to spread the dra-
matic benefits from chemotherapy from these selected
chemotherapy curable malignancies to the wider range of
cancers by overcoming chemotherapy resistance. Despite
this work, there has been no increase in the range of
chemotherapy curable malignancies, little routine clinical
application of these approaches and now the majority of
new oncology drugs are molecularly targeted therapies
rather than additional new or improved classical cyto-
toxic agents.
This raises the issue of whether the development and
range of activity of classical cytotoxic drugs is now nearly
complete or if new accompanying technologies can allow
the mode of action and range of effective targets to be
significantly improved.
In terms of extending chemotherapy curability to other
malignancies with classical cytotoxic chemotherapy drugs
the observation that no more effective therapies have been
introduced since 1982 would argue that the development
of this technology is near complete. However if the inter-
pretation of the information in this paper is correct, there
are within the majority of cancer cells the genes present
that could turn the current modest benefits from chemo-
therapy drug treatment potentially into something much
more dramatic, however the technology to achieve this is
challenging.
One could hypothesis that if the pro-apoptotic path-
ways associated with these unique genetic event could
be activated in other types of cancer cells then the bene-
fits from chemotherapy could be dramatically improved.
Whilst it is difficult to envisage employing the processes
supporting nuclear fusion and gastrulation, the processes
supporting meiosis and VDJ rearrangement may be
more realistically accessible.
It has previously been noted that radiotherapy treat-
ment to fibroblast and lymphoma cells can result in the
expression of meiosis related proteins and that the com-
bination of DNA damage and meiosis related proteins
can only be tolerated by cells with mutated p53 path-
ways. In cells with intact p53 the combination of DNA
damage and meiosis leads to apoptosis [241,242]. Simi-
larly more recent data indicates that meiotic proteins
and meiotic depolypoidization division can occur after
radiation induced DNA damage in a wider range of
tumour cell lines [243].
Whilst inducing any of these unique genetic events as
a therapeutic approach might appear fanciful, recent
data shows that a number of non-B cell malignant cells
actually express their recombined immunoglobulin genes
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undergone a tumor type repetitive pattern of VDJ re-
arrangement pattern [244-246]. Additionally it appears
that some cells can undergo a limited and atypical form
of somatic hypermutation and that measurable levels of
AID is still expressed but that ongoing mutation does
not appear to be occurring in a number of studied
breast cancer cell lines [247]. It is unclear if cancer cells
that are making immunoglobulins have any increase in
their sensitivity to chemotherapy and treatment out-
comes. These findings that the immunoglobulin gene
system is at least active in part in a number of tumor
types raises the possibility that the fuller activity with
the induction of effective apoptosis could be a novel
therapeutic strategy.
The effective treatment and cure of the rare chemo-
therapy curable malignancies has been one of the great
achievements of modern medicine, it is possible that
with a greater understanding of the processes that make
these diagnoses so sensitive to chemotherapy that the
benefits could be extended to a much wider group of
malignancies by the exploitation of the natural pathways
that should be present but not activated in most types of
malignant cells.
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